Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
華爾街頂級分析師改變了對這些知名公司的展望。如需查看所有分析師評級變化的完整情況，包括升級、降級和初始評級，請參閱我們的分析師評級頁面。
Deutsche Bank analyst David Hoang initiated coverage onKymera Therapeutics Inc(NASDAQ:KYMR) with a Hold rating and announced a price target of $120. Kymera Therapeutics shares closed at $105.25 on Wednesday. See how other analysts view this stock.
- UBS analyst Nicolas Gaudois initiated coverage onSK Hynix Inc – ADR(NASDAQ:SKHY) with a Buy rating and announced a price target of $204. SK Hynix closed at $126.79 on Wednesday. See how other analysts view this stock.
- Rodman & Renshaw analyst Michael G. King Jr. initiated coverage onActuate Therapeutics Inc(NASDAQ:ACTU) with a Buy rating and announced a price target of $6. Actuate Therapeutics shares closed at $1.08 on Wednesday. See how other analysts view this stock.
德意志銀行分析師David Hoang首次覆蓋Kymera Therapeutics Inc（納斯達克：KYMR），給予持有評級，並宣佈目標價為$120。Kymera Therapeutics股價周三收於$105.25。查看其他分析師對該股票的看法。
- 瑞銀分析師Nicolas Gaudois首次覆蓋SK Hynix Inc – ADR（納斯達克：SKHY），給予「買入」評級，並宣佈目標價為$204。SK Hynix周三收盤價為$126.79。查看其他分析師對該股票的看法。
- Rodman & Renshaw分析師Michael G. King Jr首次覆蓋Actuate Therapeutics Inc（納斯達克：ACTU），給予買入評級，並宣佈目標價為$6。Actuate Therapeutics股價周三收於$1.08。查看其他分析師對該股票的看法。
Considering buying SKHY stock? Here's what analysts think:
考慮買入SKHY股票嗎？以下是分析師的看法：
Photo via Shutterstock
圖片來自Shutterstock
(Benzinga)